Up and Coming
This feature highlights changes in clinical trial organizations’ personnel.
John Chin is now the chief business officer of Antengene, joining the company after serving as the country general manager at Celgene China.
Aridis has named Michael A. Nazak its new chief financial officer. Prior to this appointment, Nazak served as the company’s vice president of finance. Before joining Aridis, Nazak was the senior vice president of finance at Coherus Biosciences. Nazak will be replacing Fred Kurland, who has recently retired from the company.
James Hassard has been appointed to the newly created position of chief commercial officer at Arrowhead Pharmaceuticals. Since 2016 and prior to joining Arrowhead, Hassard served as senior vice president of marketing and market access at Coherus BioSciences.
Theresa G. H. Heah has been appointed the position of chief medical officer at AsclepiX Therapeutics. Prior to this role, Heah served as the chief medical officer at Applied Genetic Technologies.
AVEO Oncology has appointed Erick Lucera as chief financial officer after recently serving as chief financial officer of Valeritas.
Daniel Schneiderman has been appointed chief financial officer of AzurRx BioPharma. Schneiderman’s most recent position was chief financial officer for Biophytis, a role he held from November 2018 to December 2019.
BeyondSpring has appointed James Tonra as the firm’s new chief science officer. Tonra previously served as BeyondSpring’s senior vice president of preclinical development.
Biocon Biologics has appointed M.B. Chinappa to the position of chief financial officer of its subsidiary Biocon Biologics India. Before this appointment, Chinappa was the president of finance and chief financial officer of Biocon’s subsidiary company Syngene International.
Kevin Ostrander has been named senior vice president of business development and member of the company executive leadership team of BioDelivery Sciences. Ostrander joins the company after previously serving as the head of North America business development at Glenmark Pharmaceuticals.
Business operations of the American Biofrontera subsidiary will now be managed by Christopher Pearson, chief commercial officer USA, and Erica Monaco, chief financial officer USA. Sales, marketing and market access will be managed by Pearson, whereas finance and operations, human resources, and legal and compliance will be managed by Monaco.
Cambrex has named Robert Green as the firm’s new executive vice president and chief financial officer. Prior to this appointment, Green was the chief financial officer of General Electric Power. Shawn Cavanagh has been promoted to president and chief operating officer at Cambrex, after serving as the company’s executive vice president and chief operating officer since 2011. Additionally, Cambrex has promoted Stephan Haitz as Cambrex’s president of CDMO sales and marketing, after serving as the firm’s vice president of sales and business development.
Carisma Therapeutics has named Debora Barton as the company’s new chief medical officer. Prior to this appointment, Barton was senior vice president of clinical and safety at Iovance Biotherapeutics. Carisma Therapeutics has also appointed Tom Wilton to the role of chief business officer. Previously, Wilton was the chief business officer of LogicBio Therapeutics, Inc.
Yong Fan has been named the senior vice president of global regulatory affairs of CARsgen Therapeutics. Before accepting this appointment, Fan was A2Z Reg Solutions’ senior consultant and owner and a member of ISCT Legal and Regulatory Affairs North America Committee.
Columbus Organization has promoted Jeff Klimaski to the role of CEO and president. Prior to this promotion, Klimaski served as the company’s president and chief operating officer.
ControlRad, a medical technology company based in Atlanta, has named Peter Pizzo as the firm’s chief financial officer. Recently, Pizzo was the chief financial officer of Cartiva. ControlRad has also named Joe Ross as vice president of marketing. Ross most recently served as Zimmer Biomet’s general manager of the company’s spine division. Additionally, Amy Lazarus was named the company’s new vice president of USA operations. Lazarus’ prior appointment was managing director at ArchPoint Consulting.
Melissa Landon has joined Cyclica as the company’s new vice president, chief strategist. Before taking this appointment, Landon was the director of applications science at Schrödinger.
Enzo Biochem has named Rebecca J. Fisher to the company’s board of directors, replacing newly retired board member Gregory M. Bortz. Fisher is the chief financial officer of Bellevue Hospital in New York. Enzo has appointed Fisher to the audit, compensation and nominating/governance committees, and she also now serves as the chair of the audit committee.
Ling Zhen has joined Fountain Medical, a China-based CO, as the company’s new co-chairman of its board of directors as well as the company’s new CEO. Prior to joining Fountain, Zhen served as a partner at Draper Dragon Venture Group and also spent more than 12 years at IQVIA in the role of global senior vice president and the general manager of Greater China.
Helen Sabzevari has been named the CEO of Intrexon, now known as Percigen. Sabzevari was previously the president of the company’s subsidiary.
Invicro/Konica Minolta Precision Medicine
Matthew Silva has been appointed CEO of Invicro, a Konica Minolta company. Silva, who has also recently joined the company’s board, was previously the executive vice president of scientific applications at Invicro. Jack Hoppin, Invicro’s cofounder and most recent CEO, will be replaced by Silva. Hoppin will now serve as the president of Konica Minolta Precision Medicine.
Dave Lemus has been named Ironshore Pharmaceuticals’ new chief financial officer. In the past 20 years, Lemus held several executive management roles at various pharmaceutical and biotechnology firms. Ironshore has also promoted Peter Lammers to the position of chief commercial officer. After joining Ironshore from IQVIA, Lammers was the company’s senior vice president of commercial operations.
Kirsten Flowers has been named chief commercial officer at Kura Oncology, joining the company after serving as head of commercial operations at Array Biopharma.
Kent Hawryluk has been appointed to the position of president and chief executive officer of MBX Biosciences. Hawryluk, a co-founder and member of MBX’s board of directors, was also a co-founder and most recently chief business officer of Avidity Biosciences. MBX has also named Greg Davis, to the position of vice president of product development. Davis previously served as vice president of CMC, regulatory and quality at Calibrium.
Mirati Therapeutics has announced the appointment of Daniel R. Faga to the position of executive vice president and chief operating officer. Most recently, Faga was the chief business officer at Spark Therapeutics. Benjamin J. Hickey was appointed as Mirati’s executive vice president and chief commercial officer. Previously, Hickey was the senior vice president and chief commercial officer at Halozyme Therapeutics. Additionally, Mirati has promoted Vickie S. Reed to the position of senior vice president of finance and chief accounting officer. Mirati has also promoted Jessica M. Corson to the role of vice president of business development.
Momenta Pharmaceuticals has appointed Young Kwon, the company’s chief business officer, to the new position of chief financial and business officer. This change comes after Momenta’s consolidation of key financial and business functions under Kwon.
Phathom Pharmaceuticals has appointed Martin J. Gilligan as the firm’s chief commercial officer. Most recently, Gilligan was the corporate vice president at Celgene.
Keith Gottesdiener, CEO of Rhythm Pharmaceuticals, has announced his departure from the company following completion of Rhythm’s new drug application. Gottesdiener’s move will likely come at the end of the first quarter.
SGI-DNA has appointed Brian Donnelly to the position of chief commercial officer. Previously, Donnelly was the global head of customer solutions and head of global commercial strategy at Illumina.
Humphrey Gardner has been named Silicon Therapeutics’ new chief medical officer. Prior to this appointment, Gardner was the chief of medical oncology at Evelo Biosciences. In addition, Silicon has named Christopher Borella as the company’s new vice president and head of operations. Borella recently spent over eight years at Agios Pharmaceuticals, where he served as the company’s head of early-stage program management. Huafeng Xu has been appointed to the position of Silicon’s chief technology officer. Before joining Silicon, Xu sent 12 years at D. E. Shaw Research.
Turning Point Therapeutics
Homa Yeganegi has been appointed to the roles of senior vice president, project team leader and head of medical affairs at Turning Point Therapeutics. Previously, Yeganegi was senior vice president and global program leader at Halozyme.